What's New at the LA Capitol

As cancer care professionals who experience the challenges of providing quality cancer care first-hand, LOS members are well positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. State and federal legislation can have a significant impact on the financial viability of local cancer programs, which is why it's so important that our members make their voices heard. 

We want to hear from you! If there is a specific piece of legislation you want to know more about, an important resource we're missing, or if you want to get more involved, please contact us!

Governor Edwards Signs SB 366 into Law 
June 27, 2022

Earlier this month, Governor John Edwards signed SB 366 into law, which will will offer additional protections to patients by adding a savings clause to protect a patient's eligibility to contribute to an HSA and ensures that cost-sharing assistance will count toward out-of-pocket obligations.

Governor Edwards to Sign Prior Authorization Bill

May 24, 2022

Lawmakers in Louisiana unanimously passed SB 112, a bill that requires health insurers to reduce burdensome delays in approving and making payments for covered healthcare services. The bill instructs insurers to implement and maintain a program that allows for selective application of prior authorization requirements based on a provider's performance and adherence to evidence-based medicine. LOS and ASCO submitted a joint letter in support of the legislation to members of the House of Representatives. The bill now heads to Governor Edwards for approval.

Read the Letter 

LOS Joins 400+ Organizations in Support of MCED Legislation

May 5, 2022

The Louisiana Oncology Society (LOS) joined more than 400 organization from all 50 states to urge Congress to pass the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act (H.R.1946/S.1873) this year. This legislation would create a pathway for MCED tests to be covered by the Medicare program following approval by the Food and Drug Administration (FDA).

Read the Letter